| Date | Title | Description |
| 13.09.2024 | Rwandan startup Kasha raised additional funds to expand its digital healthcare services | In order to support its growth into more African nations, Rwandan startup Kasha, a digital platform for last-mile access to healthcare, has obtained equity funding from Sanofi Global Health Unit’s Impact Investment Fund.
Kasha, a digital re... |
| 12.09.2024 | Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers | Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
Paris, France, and Houston, Texas, September 12, 2024. As part of its effort to develop innovative treatments for people... |
| 12.09.2024 | Communiqué de presse : Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares | Accord de licence entre Sanofi, RadioMedix et Orano Med pour le développement d’une nouvelle génération de radiothérapies internes vectorisées contre les cancers rares
Paris (France) et Houston (Texas), le 12 septembre 2024. Dans le cadre d... |
| 12.09.2024 | Moderna expects up to $3.5 billion in 2025 sales | Healthcare & PharmaceuticalsCommercial Strategy
Public Health
Moderna expects up to $3.5 billion in 2025 sales
By Patrick WingroveSeptember 12, 202410:15 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin... |
| 12.09.2024 | Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 12, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatme... |
| 11.09.2024 | Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU | Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatm... |
| 11.09.2024 | Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU | Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU Confirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatm... |
| 11.09.2024 | Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study | Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults with moderate-to-seve... |
| 11.09.2024 | Communiqué de presse : Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée | Dupixent : améliorations significatives du prurit et de l’urticaire confirmées par une étude de phase III chez des patients présentant une urticaire chronique spontanée Cette deuxième étude pivot menée chez des patients n’ayant jamais été t... |
| 11.09.2024 | Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) | Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compar... |
| 11.09.2024 | Communiqué de presse : Dupixent est le premier et le seul agent biologique à obtenir des améliorations significatives de la rémission de la maladie et des symptômes dans l’étude pivot sur des patients... | Dupixent est le premier et le seul agent biologique à obtenir des améliorations significatives de la rémission de la maladie et des symptômes dans l’étude pivot sur des patients atteints de pemphigoïde bulleuse L’étude a satisfait aux critè... |
| 11.09.2024 | Press Release: Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study | Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal study Study met the primary and all key secondary endpoints in adults with moderate-to-seve... |
| 11.09.2024 | Innovent Delivers Oral Presentation on Phase 1 Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer at the 2024 WCLC | SAN FRANCISCO and SUZHOU, China, Sept. 11, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for... |
| 11.09.2024 | Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial | Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
Dupixent is the first medicine to show significant ste... |
| 11.09.2024 | Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial | Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
Dupixent is the first medicine to show significant ste... |
| 11.09.2024 | Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU) | Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compar... |
| 10.09.2024 | NanoSyrinx: A New Dawn in Biotech with £10 Million Funding | In the world of biotechnology, innovation is the lifeblood. Today, a new player is making waves. NanoSyrinx, a synthetic biology company based in Coventry, UK, has successfully raised approximately £10 million (around $13 million) in a rece... |
| 10.09.2024 | NanoSyrinx Closes Approx. £10M Financing | NanoSyrinx, a Coventry, UK-based synthetic biology company, raised approx. £10M in funding.
The round was led by BGF, Octopus Ventures and M Ventures, with participation from new corporate investor, Eli Lilly and Company, and existing inves... |
| 10.09.2024 | The invisible burden of type 1 diabetes through the eyes of a caregiver | (BPT) - Sponsored by Sanofi
Caregiving for those with type 1 diabetes is more than a responsibility, it’s a full-time job, requiring around-the-clock care and attention. From monitoring your loved one’s blood sugar, to managing food intake,... |
| 10.09.2024 | Communiqué de presse : Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône | Sanofi inaugure la première usine modulable de vaccins et biomédicaments au monde à Neuville-sur-Saône
Paris, le 10 septembre 2024. En présence du Président de la République, Emmanuel Macron, Sanofi a inauguré ce jour à Neuville-sur-Saône (... |
| 10.09.2024 | Innovent Delivers Oral Presentation of Updated Results from a Pivotal Phase 2 Study of Dupert® (Fulzerasib) in Patients with Advanced Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation | SAN FRANCISCO and SUZHOU, China, Sept. 10, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for... |
| 10.09.2024 | NanoSyrinx closes c. £10 million GBP financing and appoints Dr. Edwin Moses as Chairman | Round co-led by BGF, Octopus Ventures and M Ventures, with support from new corporate investor, Eli Lilly and Company, and existing investors, IQ Capital and Meltwind
Appointment of Edwin Moses as Chairman to support the leadership team in ... |
| 03.09.2024 | Pharmaceutical Market: Trends, Segmentation, and Growth Opportunities | Share
Tweet
Share
Share
Email
In recent years, the pharmaceutical market has witnessed remarkable growth and transformation, driven by technological advancements, evolving consumer needs, and the global push for better healthcare solutions.... |
| 02.09.2024 | Innovent Annouces Multiple Clinical Study Results of Mazdutide to be Presented at the EASD 2024 | SAN FRANCISCO and SUZHOU, China, Sept. 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for ... |
| 02.09.2024 | Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis | Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
In the HERCULES study, tolebrutinib met the primary end... |
| 02.09.2024 | CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament qui a permis d’observer une réduction de l’accumulation du handicap chez des p... | Le tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase III HERCULES ; premier et seul médicament ayant permis d’observer une réduction de l’accumulation du handicap chez des personnes présentant une sclérose en plaqu... |
| 02.09.2024 | Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis | Tolebrutinib meets primary endpoint in HERCULES phase 3 study, the first and only to show reduction in disability accumulation in non-relapsing secondary progressive multiple sclerosis
In the HERCULES study, tolebrutinib met the primary end... |
| 29.08.2024 | Innovent and Lilly: Pioneering Paths in Biopharmaceuticals | In the ever-evolving landscape of biopharmaceuticals, two companies stand out: Innovent Biologics and Eli Lilly. Both are making waves, each with a unique approach to tackling pressing health issues. Innovent, based in Suzhou, China, is car... |
| 29.08.2024 | Navigating the New Normal: COVID Vaccines and Creative Leadership in Healthcare | The landscape of healthcare marketing is shifting. Imre, a prominent brand engagement agency, has made significant strides by appointing Tracy Zuto and Malia Baker as key creative leaders. Their arrival signals a commitment to innovative, i... |
| 29.08.2024 | Understanding the toll on adults diagnosed with type 1 diabetes; new survey findings | (BPT) - Sponsored by Sanofi
Every year, tens of thousands of Americans are newly diagnosed with type 1 diabetes, an autoimmune disease characterized by the immune system attacking insulin-producing cells in the pancreas.
For many, that diag... |
| 29.08.2024 | Innovent to Present Clinical Data of Multiple Novel Molecules at WCLC and ESMO 2024 | SAN FRANCISCO and SUZHOU, China, Aug. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 28.08.2024 | GoComet Named Top Employer at 2024 GCC Workplace Awards | Ayush Lodhi, Chief Technology Officer - GoComet accepting the 2024 GCC Workplace Award in the category of Employee Rewards and Recognition
GoComet Honoured as a Top Employer Alongside ABB, Sanofi, G2, and Hitachi Energy India at the 2024 GC... |
| 28.08.2024 | Innovent Announces 2024 Interim Results and Business Updates | Strong commercial performance and significant pipeline milestones
support sustained growth and innovation
SAN FRANSISCO and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopha... |
| 28.08.2024 | Imre announced two new appointments to Strengthen Brand AOR Expertise | Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of two senior creative leaders, as the agency strengthens its position as a distinct choice for agency-of-record assignments in healthc... |
| 27.08.2024 | 3 High-Potential Biotech Stocks Under $10 The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could ... | The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCry... |
| 27.08.2024 | Imre Appoints Powerhouse Leaders Tracy Zuto and Malia Baker and Strengthens Brand AOR Expertise | New Additions Reflect Commitment to Creative Excellence and Healthcare Industry Leadership
NEW YORK, Aug. 27, 2024 /PRNewswire/ -- Imre continues its commitment to cutting-edge creative that builds brand engagement with the appointment of t... |
| 26.08.2024 | Adlook Announces Viktor Zawadzki as New VP of Platform Partnerships | Adlook, a next-generation brand growth platform, is pleased to announce that Viktor Zawadzki has been appointed as the Vice President of Platform Partnerships. Viktor transitions into this role following his successful tenure as Vice Presid... |
| 22.08.2024 | China's First Approved KRAS G12C Inhibitor: Innovent Announces the Approval of Dupert® (Fulzerasib) by the National Medical Products Administration of China | SAN FRANCISCO and SUZHOU, China, Aug. 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for ... |
| 22.08.2024 | Global Genes' Annual Week in RARE Event Heading to Kansas City | Global Genes
Global Genes is taking Week In RARE on the road to Kansas City, after having hosted this annual event in California for over 12 years. Moving the location annually will help make the event more accessible and equitable to the g... |
| 17.08.2024 | KNIME: Open-Source Data Science And AI Company Raises $30 Million | KNIME, one of the leading open-source data science and AI companies, announced it has raised additional funding from its longstanding investor, Invus. Since the last announcement, Invus has invested another $30 million, bringing the total f... |
| 15.08.2024 | Invus invests additional $30M in Knime |
KNIME helps everybody make sense of data. Its free and open-source KNIME Analytics Platform enables anyone – from business to technical and data backgrounds – to intuitively work with data. KNIME Hub is the commercial complement to KNIME A... |
| 08.08.2024 | Fierce Competition and Technological Innovation Drive Diabetes Care Devices Market Towards Explosive Growth | OEMs Leading the Charge with AI-Equipped Technology and Novel Business Strategies
SAN ANTONIO, Aug. 8, 2024 /PRNewswire/ -- The diabetes care devices industry is witnessing a dynamic evolution, marked by intense competition among establishe... |
| 08.08.2024 | Press Release: Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant | Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant Sarclisa (isatuximab) in combination with standard-of-care lenalidomide, bo... |
| 08.08.2024 | Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights | Achieved total revenue of $415 million in the second quarter of 2024 and ended the period with $1.1 billion in Cash
Filed with the U.S. FDA and EMA for authorization of updated 2024-2025 formula COVID-19 vaccine
Received $570 million in upf... |
| 07.08.2024 | KNIME's Bold Leap into the Future of AI Governance | In the fast-paced world of artificial intelligence, the race is on. Companies are scrambling to harness the power of AI while managing its risks. KNIME, a leader in open-source data science, has just made a significant move. The company sec... |
| 06.08.2024 | Open-source data science platform Knime raises $30M to seize opportunity in generative AI
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mi... | Open-source data science platform provider Knime AG said today it has closed on a new, $30 million investment from its longtime backer Invus.
The round is the first major investment the company has received since Invus led its initial Serie... |
| 06.08.2024 | KNIME Secures Investment to Accelerate Enterprise AI Governance and ModelOps | KNIME, one of the leading open-source data science and AI companies, has raised additional funding from its longstanding investor Invus. Since the last announcement, Invus invested another $30M, bringing total funding to $50M. This will all... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 05.08.2024 | QBIOTICS WELCOMES STEPHEN DOYLE AS CHIEF EXECUTIVE OFFICER | Stephen Doyle has more than 24 years of experience in the global pharmaceutical industry, including leadership positions with companies such as Sanofi Aventis and Boehringer Ingelheim. He was most recently Chief Business Officer at Aslan Ph... |
| 03.08.2024 | Tech Giants Stumble as Pharma Industry Rises in Germany | July 2024 was a month of turbulence for the tech giants. The once soaring market caps of companies like Alphabet and Microsoft took a nosedive. Investors, once enamored with the promise of artificial intelligence, began to question the sust... |
| 02.08.2024 | Seasoned chairpersons and board members back life sciences startups |
Anaveon, a clinical-stage company specializing in developing treatments for diseases with immune system dysfunction, focusing on biologics that modulate cytokine functions to provide therapeutic benefit has appointed former Chair and CEO o... |
| 01.08.2024 | Germany Attracts Another Billion-Euro Pharma Project | French pharmaceutical giant Sanofi has confirmed it will invest 1.3 billion euros to expand insulin production in the western German city of Frankfurt am Main.
BERLIN, Aug. 1, 2024 /PRNewswire/ -- Sanofi says the expansion will encompass ar... |
| 29.07.2024 | Diving Into Rare Disease: ELAVAY Highlights Leading Organizations in Rare Disease Partnerships and Patient Advocacy | The Top Organizational Rare Disease Focused Patient Advocacy Teams 2024
Elavay: Patient Insights. Elevated Healthcare
Archo Advocacy, LLC
Transforming Rare Disease Care through Collaborative Innovation and Patient Advocacy MOUNT PLEASANT, S... |
| 26.07.2024 | Advancing Dermatological Research: The American Skin Association's 2024 Grants**
** | ** The American Skin Association (ASA) has taken a bold step forward in the fight against skin diseases. On July 22, 2024, the ASA announced its 2024 research grants, a lifeline for scientists dedicated to understanding and treating skin co... |
| 26.07.2024 | BioVaxys and Innovent: Pioneering New Frontiers in Immunotherapy and Diabetes Treatment**
** | ** In the ever-evolving landscape of biopharmaceuticals, two companies are making waves: BioVaxys Technology Corp. and Innovent Biologics. Each is tackling significant health challenges with innovative approaches. BioVaxys is focused on imm... |
| 26.07.2024 | BioVaxys and American Skin Association: Pioneering Paths in Medical Research**
** | ** In the ever-evolving landscape of medical research, two organizations stand out: BioVaxys Technology Corp. and the American Skin Association (ASA). Each is carving a niche in their respective fields, focusing on innovative solutions for ... |
| 26.07.2024 | Global Markets in Turmoil: A New Era of Caution**
** | ** The global financial landscape is shifting. Markets are feeling the tremors of a stock rout that extends beyond the tech giants. Investors are bracing for impact as uncertainty looms large. On July 25, 2024, the world watched as stock ma... |
| 26.07.2024 | Innovent and WeComput Announce Strategic Partnership to Advance AI-Driven Drug Discovery and Development | SAN FRANCISCO and SUZHOU, China, July 26, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 25.07.2024 | Press Release: Online availability of Sanofi’s half-year financial report for 2024 | Online availability of Sanofi’s half-year financial report for 2024
Paris, July 25, 2024. Sanofi announces that its half-year financial report for the period ending June 30, 2024 is now available and has been filed with the French market re... |
| 25.07.2024 | Morning Bid: Stock rout spreads beyond tech | European MarketsMorning Bid: Stock rout spreads beyond tech
By ReutersJuly 25, 20245:12 AM UTCUpdated ago
Text
Small Text
Medium Text
Large Text
Share
X
Facebook
Linkedin
Email
Link
A share trader checks his screens at the stock exchange in... |
| 25.07.2024 | Morning Bid: Stock rout spreads beyond tech | A look at the day ahead in European and global markets from Kevin Buckland
The global equity sell-off looks set to extend into Europe on Thursday although the region may be spared the carnage in parts of Asia, where Japan's Nikkei tumbled a... |
| 23.07.2024 | BIOVAXYS ANNOUNCES ISSUANCE OF DPX RELATED PATENT FROM THE U.S. PATENT AND TRADEMARK OFFICE | VANCOUVER, BC, July 23, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that the United States Patent and Trademark Office ("USPTO") has ... |
| 22.07.2024 | Innovent Announces the Second Phase 3 Trial of Mazdutide in Chinese Patients with Type 2 Diabetes Met Study Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA | SAN FRANCISCO and SUZHOU, China, July 22, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 22.07.2024 | Sanofi: Information concerning the total number of voting rights and shares – June 2024 | Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financi... |
| 22.07.2024 | AMERICAN SKIN ASSOCIATION ANNOUNCES 2024 RESEARCH GRANTS FOR SKIN CANCER AND DISEASES | NEW YORK, July 22, 2024 /PRNewswire/ -- American Skin Association has announced the names of the three Investigative Scientist Awards. Andrew Ji, MD of Icahn School of Medicine at Mount Sinai was awarded the ASA Sanofi Investigative Scienti... |
| 18.07.2024 | Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million | Enzymatica’s Board of Directors decides on a new rights issue of approximately SEK 130 million
Thu, Jul 18, 2024 07:45 CET Report this content
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATE... |
| 18.07.2024 | NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A | NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A
Thu, Jul 18, 2024 08:00 CET Report this content XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophyla... |
| 17.07.2024 | Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A | NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor levels with once-weekly dosing in children under 1... |
| 16.07.2024 | Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance | Sobi Q2 2024 report: Strong delivery driven by robust portfolio performance
Tue, Jul 16, 2024 08:00 CET Report this content
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2024
Second Quarter 202... |
| 11.07.2024 | Baidu Founder's Life Sciences and AI Firm Wraps Up Fundraiser | (Yicai) July 11 -- BioMap, a life sciences and artificial intelligence model firm established by Robin Li, founder and chief executive officer of Chinese tech giant Baidu, has completed a new financing round.
Yicai, who learned about BioMap... |
| 10.07.2024 | Antonin (Tony) de Fougerolles appointed as new Chair of etherna | Brings foundational experience in mRNA and LNP therapeutics given prior executive leadership roles at Moderna & Alnylam
Will take an active role in expanding partnerships with biopharma
Integrated partnership offering to customers remai... |
| 10.07.2024 | Flagship Pioneering Expands Leadership Team with Key Appointments and Promotions | CAMBRIDGE, Mass., July 10, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced additions to its leadership team through key executive appointments and promotions. Today's personnel announcement acco... |
| 05.07.2024 | Innovent and IASO Bio Enhance Strategic Collaboration in Cell Therapy | SAN FRANCISCO and SUZHOU, China, July 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 03.07.2024 | Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD | Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent... |
| 03.07.2024 | Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD | First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-r... |
| 03.07.2024 | Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD | First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-r... |
| 03.07.2024 | Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD | Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent... |
| 03.07.2024 | Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne | Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne Première approbation au monde de Dupixent pour le traitement de la BPCO non contrôlée de l’adulte avec éosinophilie sanguine él... |
| 02.07.2024 | Innovent Announces Oral Presentation at the ESMO Gastrointestinal Cancers Congress 2024 on Latest Clinical Data of Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junctio... | SAN FRANCISCO and SUZHOU, China, July 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for t... |
| 01.07.2024 | Sanofi планирует инвестировать в Германию до $1,6 млрд | Как сообщила в понедельник газета Handelsblatt, Французская фармацевтическая компания Sanofi близка к принятию решения об инвестировании от €1,3 млрд до €1,5 млрд в крупную производственную площадку во Франкфурте, Германия, где она выпускае... |
| 28.06.2024 | Innovent Provides Interpretation and Updates on Clinical Data from Mazdutide GLORY-1 Study and General Biomedicine Pipeline | SAN FRANCISCO and SUZHOU, China, June 28, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 27.06.2024 | Formation Bio: Revolutionizing Pharma with AI | Formation Bio, a NYC-based tech-driven and AI-native pharma company, recently secured a staggering $372M in Series D funding. This funding, led by a16z and with significant participation from Sanofi, marks a significant milestone for the co... |
| 26.06.2024 | Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine | Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year
Dupixent is the first and only treatment indicated for EoE in the U.S. f... |
| 26.06.2024 | Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans | Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans La majorité des patients de cette tranche d’âge traités par Dupixent pour une œsop... |
| 26.06.2024 | Two Studies Show Mixed Progress Against EoE | Experts at Cincinnati Children's play key roles in one trial that supports dupilumab use for children under 12 and another study showing no relief for people taking benralizumab.
Both studies appear in The New England Journal of Medicine.
C... |
| 26.06.2024 | Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM | Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with im... |
| 26.06.2024 | AI-focused Formation secures Sanofi-backed $372M series D to license more drugs | Megarounds have been few and far between in 2024, but Formation Bio has managed to draw in an impressive $372 million series D as the AI-focused biotech seeks to expand its pipeline.
AI companies like to promise the world, but Formation’s o... |
| 26.06.2024 | AI-powered drug development startup Formation Bio raises $372M
Your vote of support is important to us and it helps us keep the content FREE.
One click below supports our mission to provide free, deep... | Formation Bio Inc., a startup using artificial intelligence to speed up drug development, today announced that it has closed a mammoth $372 million investment.
Andreessen Horowitz led the Series D funding round. It was joined by pharmaceuti... |
| 26.06.2024 | Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM | Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with im... |
| 26.06.2024 | Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine | Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year
Dupixent is the first and only treatment indicated for EoE in the U.S. f... |
| 26.06.2024 | Formation Bio secures $372MM Series D funding to grow drug pipeline and continue expanding AI-driven drug development platform | NEW YORK, June 26, 2024 /PRNewswire/ -- Formation Bio, a tech-driven and AI-native pharma company, announced today that it has raised $372MM of Series D financing. The financing was led by a16z with significant participation from Sanofi. Cu... |
| 25.06.2024 | Press Release: Availability of the Q2 2024 Aide-mémoire | Availability of the Q2 2024 Aide-mémoire
Paris, France – June 25, 2024. Sanofi announced that its Q2 2024 Aide-mémoire is available on the "Investors" page of the company's website:
https://www.sanofi.com/en/investors/financial-re... |
| 25.06.2024 | Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA's 84th Scientific Sessions | SAN FRANCISCO and SUZHOU, China, June 25, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 20.06.2024 | Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa | Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa
Paris, June 20, 2024. Sanofi and Biovac, a Cape Town, South Africa-based biopharmaceutical company, announce today their local manufacturing partnership to produ... |
| 20.06.2024 | BREAK THE CEILING TOUCH THE SKY® ANNOUNCES C-SUITE SPEAKER LINEUP FOR JULY 16 AMERICAS SUMMIT | NEW YORK, June 20, 2024 /PRNewswire/ -- House of Rose Professional Pte. Ltd. has announced the C-Suite speaker lineup for its 2024 Americas Edition of Break the ceiling touch the sky® – the success and leadership summit for women to be held... |
| 20.06.2024 | BREAK THE CEILING TOUCH THE SKY® ANNOUNCES C-SUITE SPEAKER LINEUP FOR JULY 16 AMERICAS SUMMIT | NEW YORK, June 20, 2024 /PRNewswire/ -- House of Rose Professional Pte. Ltd. has announced the C-Suite speaker lineup for its 2024 Americas Edition of Break the ceiling touch the sky® – the success and leadership summit for women to be held... |
| 19.06.2024 | European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A | European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A
Wed, Jun 19, 2024 08:00 CET Report this content
Sobi® today announced the European Commission has granted Marketing Authorisation for ALTU... |
| 19.06.2024 | Innovent Reports Oncology Pipeline Updates at Investor Meeting | SAN FRANCISCO and SUZHOU, China, June 19, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatmen... |
| 18.06.2024 | ViQi Appoints Dr. Tong-Ming Fu M.D., Ph.D, to its Scientific Advisory Board to Accelerate Scientific Innovation Using AI and Imaging | Dr. Tong-Ming Fu, MD, PhD
ViQi, Inc., announces the appointment of Dr. Tong-Ming Fu to the ViQi Scientific Advisory Board. This appointment will draw on Dr. Tong-Ming Fu's expertise in virology and his experience with the ViQi flagship AI-b... |
| 17.06.2024 | Sobi to present new haemophilia data at ISTH 2024 | Sobi to present new haemophilia data at ISTH 2024
Mon, Jun 17, 2024 08:00 CET Report this content
Sobi® will present new scientific data related to haemophilia at ISTH 2024, the 32nd Congress of the International Society on Thrombosis and H... |
